



## Twist Bioscience to Present at the Cowen 40th Annual Health Care Conference

February 26, 2020

SAN FRANCISCO--(BUSINESS WIRE)--Feb. 26, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a SynBio panel at the Cowen 40th Annual Health Care Conference on Tuesday, March 3 at 2:35 p.m. Eastern Time in Boston. In addition to the panel, the company will present on Wednesday, March 4 at 10:00 a.m. Eastern Time.

The presentation will be webcast live and can be accessed by visiting the "Presentations" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 90 days following the conclusion of the live event.

### About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200226005298/en/): <https://www.businesswire.com/news/home/20200226005298/en/>

#### Investor Contact:

Argot Partners  
Maeve Conneighton  
212-600-1902  
[maeve@argotpartners.com](mailto:maeve@argotpartners.com)

#### Media Contact:

Angela Bitting  
925- 202-6211  
[media@twistbioscience.com](mailto:media@twistbioscience.com)

Source: Twist Bioscience Corporation

#### Investor Contact:

Argot Partners  
Maeve Conneighton  
212-600-1902  
[maeve@argotpartners.com](mailto:maeve@argotpartners.com)

#### Media Contact:

Angela Bitting  
925- 202-6211  
[media@twistbioscience.com](mailto:media@twistbioscience.com)